Resolution Therapeutics to Showcase Breakthrough Data at AASLD 2024
Exciting Presentations by Resolution Therapeutics at AASLD 2024
Resolution Therapeutics Limited, renowned for its pioneering work in macrophage therapy, is thrilled to announce its upcoming presentations at the prestigious American Association for the Study of Liver Disease (AASLD) The Liver Meeting® 2024. This significant event will feature groundbreaking research highlighting the potential of autologous macrophage therapy in treating liver disease, showcasing their commitment to improving patient outcomes.
Overview of the Presentations
At this year's meeting, Resolution will present two major abstracts. The first is an oral presentation summarizing pivotal findings from the three-year MATCH Phase 2 trial exploring the safety and efficacy of their macrophage-based treatment. The second will be a focused poster presentation, which will delve into preclinical data supporting the use of RTX001, a cutting-edge engineered macrophage therapy designed specifically for patients with end-stage liver disease.
Oral Presentation Highlights
Autologous Macrophage Therapy
Professor Stuart Forbes, a leading figure in transplantation and regenerative medicine, will be delivering an oral presentation detailing extended data from the MATCH Phase 2 trial. This trial reveals how autologous macrophage therapy significantly reduces major clinical outcomes for patients suffering from compensated cirrhosis.
Title: Autologous macrophage therapy decreases major clinical outcomes in patients with compensated cirrhosis: extended data from a randomized controlled Phase 2 trial
Author: Stuart J. Forbes, MB CHB, FRCP(Ed), PhD
Date/Time: Monday 18 November 2024, 5:00 PM – 6:30 PM PDT
Poster Presentation Insights
RTX001's Preclinical Proof of Concept
Dr. Lara Campana, a co-founder and the Vice President of Research Operations at Resolution, will present a poster that outlines the preclinical proof of concept for RTX001, emphasizing its safety and efficacy as an advanced therapy for end-stage liver disease.
Title: Preclinical proof of concept of safety and efficacy for RTX001, a novel autologous macrophage cell therapy product for end-stage liver disease
Author: Lara Campana, Ph.D.
Date/Time: Sunday 17 November 2024, 8:00 AM – 5:00 PM PDT
Engagement Opportunities at AASLD
The conference offers an excellent opportunity for members of the Resolution senior leadership team to engage with attendees to discuss the novel therapies being developed. Interested participants are encouraged to reach out for meetings to explore the company’s pioneering approach to macrophage therapy.
About Resolution Therapeutics
Resolution Therapeutics is dedicated to unlocking the healing potential of macrophage therapy for treating inflammatory and fibrotic diseases. By leveraging a proprietary cell characterization and engineering platform, the company develops autologous macrophages that exhibit unique pro-regenerative properties. Their lead product candidate, RTX001, demonstrates first-in-class potential owing to preclinical data showcasing its anti-fibrotic and anti-inflammatory benefits over standard macrophages. The company is also exploring applications beyond liver diseases, aiming to expand the therapeutic benefits of engineered macrophages.
Understanding AASLD's Role
The American Association for the Study of Liver Disease (AASLD) serves as a foremost organization for specialists and healthcare professionals committed to combating liver diseases. Through extensive research and educational initiatives, AASLD enhances treatment options for countless patients enduring liver conditions. The organization’s conferences and training programs promote advances in hepatology, contributing to impactful scientific developments.
Frequently Asked Questions
What is the main focus of Resolution Therapeutics?
Resolution Therapeutics focuses on macrophage therapy for inflammatory and fibrotic diseases, particularly for end-stage liver conditions.
What significant data will be presented at AASLD 2024?
The company will present data from the MATCH Phase 2 trial demonstrating the effectiveness of autologous macrophage therapy in compensated cirrhosis and details about their RTX001 candidate.
Who will present the oral findings at AASLD?
Professor Stuart Forbes will deliver the oral presentation on the findings from the MATCH Phase 2 trial.
When and where is the liver meeting taking place?
The AASLD The Liver Meeting® 2024 is scheduled to be held from 15-19 November.
How can attendees connect with Resolution Therapeutics at the conference?
Attendees can reach out to Resolution's leadership team for discussions about their innovative macrophage therapies and ongoing research projects.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- Exploring the Future of Patient Engagement Solutions Market
- GXO Logistics Collaborates with Forum Sport to Enhance Supply Chain
- Confo Therapeutics Pioneers GPCR Targeting Innovations
- Innovative Authentication Solutions for Secure Industries Unveiled
- Keepit Announces New Chief Product Officer to Elevate Strategy
- Vitalik Buterin Advocates for Crypto Prediction Market Polymarket
- Latest ECM Trends: Market Volatility Impacts Equity Deals
- Innovative Partnership Boosts SWIR Imaging Solutions for All
- Relu Achieves FDA Clearance and CE Mark for Dental Innovation
- Celebrating a Year of Progress: Procede Software Collaboration
Recent Articles
- AstronauTx Expands Leadership Team with New Appointments
- Avassa Secures Strategic Funding with H&M Group Investment
- Ericsson to Host Q3 2024 Financial Report Briefing Session
- Virtune AB Enhances Crypto Index ETP Performance in September
- Ferring's Study Reveals Promising Treatment for Ulcerative Colitis
- Kia America Celebrates Unprecedented Sales Growth for EVs
- Alfa Laval AB Forms Nomination Committee for 2025 AGM
- Rickard Vikström of Internet Vikings Among Gaming’s Rising Stars
- Metalla Royalty & Streaming Ltd. Positioned for Growth Ahead
- a2 Milk Co's Growth Strategy Signals Strong Financial Future
- Citi Adjusts Heineken's Price Target, Sees Long-Term Potential
- Worldline's Future Growth Linked to New CEO Appointment
- Zalando Stock Gains Amidst Strong Q3. Will B2C Recovery Follow?
- Citi's Positive Upgrade for Anheuser-Busch InBev Stock Growth
- European Stocks Rise with Inflation Data Looming on Horizon
- Treatment.com AI to Showcase Innovations at Cantech Conference
- Discover the Impact of Wood Mackenzie's New Analytics Tool
- Preserved Flowers Market Growth and Future Opportunities
- Exciting Launch of $Aria Coin on the Solana Blockchain
- Kalmar Enhances Leadership Team to Propel Sustainable Growth
- JLT Mobile Computers Expands Leadership for Growth in France
- Elanders to Host Third Quarter Results Announcement Soon
- Avenir LNG's Strategic Shift Towards Shipping and Trading
- Nokia Unveils Lightspan MF-8 to Enhance Fiber Access Solutions
- Investments Update: Maj Invest Releases New Prospectuses
- Nordea Invest Prospectus Update and Key Changes Announced
- Robinhood Crypto Enhances User Experience with European Launch
- Hi-View Announces New Discoveries in Latest Exploration Results
- Awilco Drilling Plc Confirms Warrant Exercise Results
- Volt Lithium's Upcoming Conferences: Key Highlights and Insights
- SICPA Dominates Fuel Marking with Innovative Solutions
- Paul Krugman Critiques Trump's Campaign on Economic Issues
- Kyowa Kirin Unveils Strong Burosumab Benefits for XLH Patients
- Shigeru Ishiba's Leadership: Impacts on Japan-U.S. Relations
- Hafnia Limited Transitions Smoothly to Singapore Corporate Structure
- Transforming Hotel Marketing: The Cloudbeds and Mirai Alliance
- BearingPoint Achieves B Corp Certification for Sustainability
- Wolters Kluwer Elevates Richard Pulliam to Senior Executive Role
- Volt Lithium's Role in Upcoming Investor Gatherings
- Mark Cuban’s Evolving Views on Trump: A Complicated Relationship
- Tesla Drivers Can Soon Enjoy the Smart Summon Feature
- Leadership Transition at Concentric AB: What to Expect
- Cupshe Launches New Collection for Breast Cancer Awareness Month
- Neuraxpharm extends its CNS product reach in the Middle East
- Thoma Bravo's Strategic Investment in USU: A Bright Future
- Exploring Power Nickel's Promising Lion Zone Assay Results
- TaylorMade Golf Elevates Labeling Efficiency with TEKLYNX Solutions
- Innovative Use of Silicones in Automotive and Healthcare Solutions
- CME Group Introduces Innovative Micro Nikkei Futures Trading
- Joe Jonas and PlanetPlay Unite for Environmental Action